New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available

Vandana Abramson, Carlos L. Arteaga

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations

Abstract

The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.

Original languageEnglish (US)
Pages (from-to)952-958
Number of pages7
JournalClinical Cancer Research
Volume17
Issue number5
DOIs
StatePublished - Mar 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available'. Together they form a unique fingerprint.

Cite this